BR112021019155A2 - Uso do gene kdm5a e gene atrx - Google Patents

Uso do gene kdm5a e gene atrx

Info

Publication number
BR112021019155A2
BR112021019155A2 BR112021019155A BR112021019155A BR112021019155A2 BR 112021019155 A2 BR112021019155 A2 BR 112021019155A2 BR 112021019155 A BR112021019155 A BR 112021019155A BR 112021019155 A BR112021019155 A BR 112021019155A BR 112021019155 A2 BR112021019155 A2 BR 112021019155A2
Authority
BR
Brazil
Prior art keywords
gene
kdm5a
atrx
chiauranib
biomarkers
Prior art date
Application number
BR112021019155A
Other languages
English (en)
Inventor
Desi Pan
Song Shan
Xianping Lu
Zhiqiang Ning
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of BR112021019155A2 publication Critical patent/BR112021019155A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

uso do gene kdm5a e gene atrx. a presente invenção refere-se ao uso do gene kdm5a e/ou gene atrx como biomarcadores na avaliação da eficácia de chiauranibe ou orientação da administração de chiauranibe, e o uso de chiauranibe na preparação de fármacos para o tratamento de pacientes com câncer de pulmão de pequenas células com mutações gênicas no gene kdm5a ou gene atrx.
BR112021019155A 2019-03-25 2020-03-23 Uso do gene kdm5a e gene atrx BR112021019155A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910228411 2019-03-25
PCT/CN2020/080579 WO2020192606A1 (zh) 2019-03-25 2020-03-23 Kdm5a基因和atrx基因的应用

Publications (1)

Publication Number Publication Date
BR112021019155A2 true BR112021019155A2 (pt) 2022-02-15

Family

ID=72610972

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019155A BR112021019155A2 (pt) 2019-03-25 2020-03-23 Uso do gene kdm5a e gene atrx

Country Status (12)

Country Link
US (1) US20220184056A1 (pt)
EP (1) EP3950961A4 (pt)
JP (1) JP2022527895A (pt)
KR (1) KR20210143866A (pt)
CN (1) CN111733235A (pt)
AU (1) AU2020246335A1 (pt)
BR (1) BR112021019155A2 (pt)
CA (1) CA3134620A1 (pt)
MX (1) MX2021011677A (pt)
TW (1) TWI798532B (pt)
WO (1) WO2020192606A1 (pt)
ZA (1) ZA202108165B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI797426B (zh) * 2019-03-25 2023-04-01 大陸商深圳微芯生物科技股份有限公司 西奧羅尼用於小細胞肺癌的治療
CN112111577B (zh) * 2020-10-23 2022-09-06 北京诺禾致源科技股份有限公司 基于数字pcr技术的atrx和kdm5a突变检测的试剂盒、装置及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2887243C (en) * 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
AU2013355260B2 (en) * 2012-12-04 2019-07-25 Caris Mpi, Inc. Molecular profiling for cancer
KR20150130451A (ko) * 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
CN105512142A (zh) * 2014-09-26 2016-04-20 深圳华大基因股份有限公司 基因变异与药物关系数据库和数据库系统
US20180045727A1 (en) * 2015-03-03 2018-02-15 Caris Mpi, Inc. Molecular profiling for cancer
EP3265562A4 (en) * 2015-03-05 2018-12-19 TrovaGene, Inc. Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids
CN105512412A (zh) * 2015-12-11 2016-04-20 中国北方发动机研究所(天津) 一种增压发动机排气系统匹配优劣的评价方法

Also Published As

Publication number Publication date
US20220184056A1 (en) 2022-06-16
AU2020246335A1 (en) 2021-11-18
JP2022527895A (ja) 2022-06-07
KR20210143866A (ko) 2021-11-29
CN111733235A (zh) 2020-10-02
TW202035700A (zh) 2020-10-01
EP3950961A1 (en) 2022-02-09
MX2021011677A (es) 2021-10-22
CA3134620A1 (en) 2020-10-01
ZA202108165B (en) 2023-06-28
EP3950961A4 (en) 2023-01-25
WO2020192606A1 (zh) 2020-10-01
TWI798532B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112018010418A2 (pt) complexo de agente quimioterápico em microbolhas para terapia sonodinâmica
BR112018002130A2 (pt) anticorpo de domínio único e proteínas derivadas respectivas contra um ligante de morte programada (pdl1)
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
BR112012026213A8 (pt) Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
PH12015500758A1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
BR112016014126A2 (pt) compostos peptidomiméticos e conjugados de anticorpo-fármaco dos mesmos
BR112015032546A2 (pt) derivados de pirrolo[3,2-d]pirimidina para o tratamento de infecções virais e outras doenças
EA201691023A1 (ru) Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112015026095A2 (pt) métodos para controlar a dosagem de uma droga antitumoral administrada a um paciente com câncer, para administração de pelo menos uma droga antitumoral em duas doses separadas em um paciente com câncer e para seleção de pelo menos uma droga antitumoral
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112012030479A2 (pt) terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1
BR112021019155A2 (pt) Uso do gene kdm5a e gene atrx
BR112016016880A2 (pt) Combinação para tratar câncer e seu uso, kit, e composição farmacêutica
BR112018072988A2 (pt) irinotecano lipossômico para uso no tratamento de câncer de pulmão de pequenas célula
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
CY1123501T1 (el) Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
BR112016023025A2 (pt) direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3
BR112014029954A2 (pt) tratamento de tumores sólidos usando coenzima q10
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112014018450A8 (pt) Fenilimidazopirazoles substituídos e sua utilização
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN)